{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:32:41Z","timestamp":1788474761350,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009882","name":"Lombardy Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcf.2025.10.005","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T23:30:50Z","timestamp":1760657450000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Limited impact of Elexacaftor\/Tezacaftor\/Ivacaftor on CPET outcomes in an Italian cohort of people with Cystic Fibrosis: reinforcing the essential role of exercise training"],"prefix":"10.1016","volume":"25","author":[{"given":"Mariangela","family":"Retucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-5737","authenticated-orcid":false,"given":"Andrea","family":"Gramegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-2989","authenticated-orcid":false,"given":"Simone","family":"Gambazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-7927","authenticated-orcid":false,"given":"Martina","family":"Santambrogio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-6344","authenticated-orcid":false,"given":"Gianmarco","family":"Putti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9334-4555","authenticated-orcid":false,"given":"Marco","family":"Vicenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-9165","authenticated-orcid":false,"given":"Valeria","family":"Dacc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2025.10.005_bib0001","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2024.05.007","article-title":"Standards for the care of people with cystic fibrosis (CF); planning for a longer life","volume":"23","author":"Gramegna","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.005_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.10.005_bib0003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.005_bib0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.10.005_bib0005","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/j.2040-4603.2013.tb00513.x","article-title":"Exercise and type 1 diabetes (T1DM)","volume":"3","author":"Galassetti","year":"2013","journal-title":"Compr Physiol"},{"issue":"6","key":"10.1016\/j.jcf.2025.10.005_bib0006","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2024.04.010","article-title":"Changes in exercise capacity in people with cystic fibrosis after one year of elexacaftor\/tezacaftor\/ivacaftor treatment - a Danish prospective cohort","volume":"23","author":"Philipsen","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.005_bib0007","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcf.2022.05.009","article-title":"Change in exercise capacity measured by cardio-pulmonary exercise testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor\/Ivacaftor and Tezacaftor\/Ivacaftor","volume":"21","author":"Rysgaard","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.10.005_bib0008","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000439057","article-title":"Statement on exercise testing in cystic fibrosis","volume":"90","author":"Hebestreit","year":"2015","journal-title":"Respiration"},{"issue":"154","key":"10.1016\/j.jcf.2025.10.005_bib0009","first-page":"28","article-title":"ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases","author":"Radtke","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"8","key":"10.1016\/j.jcf.2025.10.005_bib0010","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","article-title":"International physical activity questionnaire: 12-country reliability and validity","volume":"35","author":"Craig","year":"2003","journal-title":"Med Sci Sports Exerc"},{"issue":"6","key":"10.1016\/j.jcf.2025.10.005_bib0011","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1183\/09031936.00150314","article-title":"An official European Respiratory Society\/American Thoracic Society technical standard: field walking tests in chronic respiratory disease","volume":"44","author":"Holland","year":"2014","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.jcf.2025.10.005_bib0012","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2025.10.005_bib0013","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2025.10.005_bib0014","first-page":"53","article-title":"ERS statement on respiratory muscle testing at rest and during exercise","author":"Laveneziana","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.10.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/824091","article-title":"Assessing exercise limitation using cardiopulmonary exercise testing","volume":"2012","author":"Stickland","year":"2012","journal-title":"Pulm Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.10.005_bib0017","series-title":"R: a language and environment for statistical computing","author":"Team","year":"2024"},{"issue":"11","key":"10.1016\/j.jcf.2025.10.005_bib0018","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis","volume":"57","author":"Causer","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00687-2023","article-title":"Impact of CFTR modulators on exercise capacity in adolescents with cystic fibrosis","volume":"10","author":"Ahmed","year":"2024","journal-title":"ERJ Open Res"},{"issue":"6","key":"10.1016\/j.jcf.2025.10.005_bib0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jcf.2013.04.012","article-title":"Reproducibility of maximal cardiopulmonary exercise testing for young cystic fibrosis patients","volume":"12","author":"Saynor","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.005_bib0021","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcf.2010.03.003","article-title":"Clinical utility of the oxygen uptake efficiency slope in cystic fibrosis patients","volume":"9","author":"Gruet","year":"2010","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.005_bib0022","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/TCRM.S391476","article-title":"Association of Oxygen therapy with the natural disease progression of cystic fibrosis: a multi-state model of the European Cystic Fibrosis Society Patient Registry","volume":"19","author":"Gambazza","year":"2023","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.005_bib0023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2023.05.009","article-title":"Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Wang","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.10.005_bib0024","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1139\/apnm-2019-0484","article-title":"Influence of sex gap on muscle strength and functional mobility in patients with cystic fibrosis","volume":"45","author":"Martinez-Garcia","year":"2020","journal-title":"Appl Physiol Nutr Metab"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.005_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcf.2022.06.012","article-title":"Cystic fibrosis related diabetes is not associated with maximal aerobic exercise capacity in cystic fibrosis: a cross-sectional analysis of an international multicenter trial","volume":"22","author":"Radtke","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.10.005_bib0026","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ppul.23906","article-title":"Relationship between exercise capacity and glucose tolerance in cystic fibrosis","volume":"53","author":"Foster","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of elexacaftor \/tezacaftor \/ ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.005_bib0028","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jcf.2017.02.007","article-title":"Peripheral muscle abnormalities in cystic fibrosis: etiology, clinical implications and response to therapeutic interventions","volume":"16","author":"Gruet","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.10.005_bib29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcf.2019.03.001","article-title":"Effects of Lumacaftor\/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis","volume":"18","author":"Savi","year":"2019","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:55:58Z","timestamp":1773903358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325024890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1569199325024890"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Limited impact of Elexacaftor\/Tezacaftor\/Ivacaftor on CPET outcomes in an Italian cohort of people with Cystic Fibrosis: reinforcing the essential role of exercise training","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}